Company News: Page (1) of 1 - 02/17/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

INVESTOR COMPLAINT: Levi & Korsinsky, LLP Reminds Investors of Ophthotech Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 13, 2017

(February 17, 2017)

NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:


To: All persons or entities who purchased or otherwise acquired shares of Ophthotech Corporation (?Ophthotech) (NASDAQ: OPHT) between May 11, 2015 and December 12, 2016. You are hereby notified that Levi & Korsinsky has commenced the class action Micholle v. Ophthotech Corporation, et al. (Case No. 1:17-cv-00210) in the USDC for the Southern District of New York. To get more information go to:

http://zlk.9nl.com/ophthotech

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.


The complaint alleges that, throughout the Class Period, Ophthotech made overtly positive representations about the effectiveness and potential of its treatment Fovista when used in combination with Lucentis, a commercially available anti-vascular endothelial growth factor agent, despite awareness that the phase 3 clinical trial of Fovista would fail to achieve its primary endpoint of change in best corrected visual acuity from baseline at 12 months over Lucentis alone. The complaint further alleges that these statements caused Ophthotech stock to trade at artificially inflated prices.

On December 12, 2016, Ophthotech announced that the trial had failed to achieve its primary endpoint, and that Fovista and Lucentis demonstrated a non-statistically significant improvement over patients only receiving Lucentis. Following this news, shares of Ophthotech fell approximately 86% to close at $5.29.

Take Action: if you suffered a loss in Ophthotech you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesnt require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firms attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.


Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com


Page: 1


Related Keywords:
Related Sites: DMN Newswire
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
HOT THREADS on DMN Forums

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved